Anti-ABL T315I monoclonal antibody
Pre-made anti-ABL T315I monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to ABL T315I/ABL1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T00348-Ab-1/ GM-Tg-hg-T00348-Ab-2 | Anti-Human ABL T315I/ABL1 monoclonal antibody | Human |
GM-Tg-rg-T00348-Ab-1/ GM-Tg-rg-T00348-Ab-2 | Anti-Rat ABL T315I/ABL1 monoclonal antibody | Rat |
GM-Tg-mg-T00348-Ab-1/ GM-Tg-mg-T00348-Ab-2 | Anti-Mouse ABL T315I/ABL1 monoclonal antibody | Mouse |
GM-Tg-cynog-T00348-Ab-1/ GM-Tg-cynog-T00348-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ABL T315I/ABL1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T00348-Ab-1/ GM-Tg-felg-T00348-Ab-2 | Anti-Feline ABL T315I/ABL1 monoclonal antibody | Feline |
GM-Tg-cang-T00348-Ab-1/ GM-Tg-cang-T00348-Ab-2 | Anti-Canine ABL T315I/ABL1 monoclonal antibody | Canine |
GM-Tg-bovg-T00348-Ab-1/ GM-Tg-bovg-T00348-Ab-2 | Anti-Bovine ABL T315I/ABL1 monoclonal antibody | Bovine |
GM-Tg-equg-T00348-Ab-1/ GM-Tg-equg-T00348-Ab-2 | Anti-Equine ABL T315I/ABL1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T00348-Ab-1/ GM-Tg-hg-T00348-Ab-2; GM-Tg-rg-T00348-Ab-1/ GM-Tg-rg-T00348-Ab-2; GM-Tg-mg-T00348-Ab-1/ GM-Tg-mg-T00348-Ab-2; GM-Tg-cynog-T00348-Ab-1/ GM-Tg-cynog-T00348-Ab-2; GM-Tg-felg-T00348-Ab-1/ GM-Tg-felg-T00348-Ab-2; GM-Tg-cang-T00348-Ab-1/ GM-Tg-cang-T00348-Ab-2; GM-Tg-bovg-T00348-Ab-1/ GM-Tg-bovg-T00348-Ab-2; GM-Tg-equg-T00348-Ab-1/ GM-Tg-equg-T00348-Ab-2 |
Products Name | Anti-ABL T315I/ABL1 monoclonal antibody |
Format | mab |
Target Name | ABL T315I |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-ABL T315I monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T00348-Ag-1 | Recombinant multi-species ABL1/ ABL T315I/ ABL protein |
Target information
Target ID | GM-T00348 |
Target Name | ABL T315I |
Gene ID | 25,11350,311860,722449,491292,101087622,540876,100069715 |
Gene Symbol and Synonyms | ABL,ABL1,BCR-ABL,bcr/abl,c-ABL,c-ABL1,CHDSKM,E430008G22Rik,JTK7,p150,v-abl |
Uniprot Accession | P00519 |
Uniprot Entry Name | ABL1_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | Cancer |
Gene Ensembl | ENSG00000097007 |
Target Classification | Kinase, Tumor-associated antigen (TAA) |
The target: ABL T315I, gene name: ABL1, also named as ABL, CHDSKM, JTK7, bcr/abl, c-ABL, c-ABL1, p150, v-abl. This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.